Radioimmunoguided surgery benefits for recurrent colorectal cancer
โ Scribed by Schlomo Schneebaum; Joseph Papo; Moshe Graif; Mimi Baratz; Jack Baron; Yehuda Skornik
- Publisher
- Springer
- Year
- 1997
- Tongue
- English
- Weight
- 746 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1068-9265
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Sixty-four patients with recurrent or metastatic colorectal cancer underwent radioimmunoguided surgery (RIGS). Thirty patients (Group A) were preoperatively injected with radiolabeled monoclonal antibody (MAb) B72.3, a whole IgG1 that reacts with tumor-associated glycoprotein (TAG-72) antigen. Thirt
Radioimmunoguided surgery (RIGS) with radiolabeled monoclonal antibodies (MoAbs) has been reported as useful in second-look colorectal cancer procedures to improve surgical decision-making by helping avoid needless extensive surgery and expanding curative resection to sites of recurrence that have b
One hundred thirty-six patients with colorectal and breast cancer were enrolled in a retrospective study using radioimmunoguided surgery (RIGS) with Iodine-125 (I 125 ) radiolabeled B72.3 (Group A, 73 patients) and F023C5 (Group B, 63 patients) monoclonal antibodies (MAbs). The correlation between i